Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center Clinical Study Evaluating the Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells（QH103） in Refractory Autoimmune Diseases

NCT06828042 is registered in ClinicalTrials.gov with Peking University Third Hospital as lead sponsor.

NCT NCT06828042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06828042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center Clinical Study Evaluating the Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells（QH103） in Refractory Autoimmune Diseases
Lead sponsor
Peking University Third Hospital
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 1, 2025
Completion date
December 31, 2027
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anca associated vasculitis (aav), antiphospholipid syndrome, inflammatory myopathies, sjogren syndrome, systemic lupus erthematosus, systemic sclerosis (ssc)